Presentaci√≥n de PowerPoint @page { } table { border-collapse:collapse; border-spacing:0; empty-cells:show } td, th { vertical-align:top; font-size:12pt;} h1, h2, h3, h4, h5, h6 { clear:both } ol, ul { margin:0; padding:0;} li { list-style: none; margin:0; padding:0;} <!-- "li span.odfLiEnd" - IE 7 issue--> li span. { clear: both; line-height:0; width:0; height:0; margin:0; padding:0; } span.footnodeNumber { padding-right:1em; } span.annotation_style_by_filter { font-size:95%; font-family:Arial; background-color:#fff000; margin:0; border:0; padding:0; } * { margin:0;} .gr1 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr10 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.13cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; } .gr11 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr12 { font-size:24pt; writing-mode:lr-tb; } .gr13 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr14 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr15 { font-size:24pt; writing-mode:lr-tb; } .gr16 { font-size:24pt; writing-mode:lr-tb; } .gr17 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr18 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr19 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr2 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr20 { font-size:24pt; writing-mode:lr-tb; } .gr21 { font-size:24pt; writing-mode:lr-tb; min-height:9.857cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr22 { font-size:24pt; writing-mode:lr-tb; } .gr23 { font-size:24pt; writing-mode:lr-tb; min-height:10.624cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr24 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr25 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr26 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr27 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr28 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr3 { font-size:24pt; writing-mode:lr-tb; } .gr4 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr5 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr6 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr7 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr8 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr9 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .P1 { font-size:14pt; } .P10 { margin-left:0cm; margin-right:0cm; text-indent:0cm; } .P11 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P12 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P13 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; text-indent:0cm; } .P14 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0.176cm; line-height:100%; text-indent:0cm; } .P15 { margin-left:0cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; text-indent:0cm; } .P16 { margin-left:0cm; margin-right:0cm; text-indent:0cm; } .P17 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-align:left ! important; text-indent:0cm; } .P18 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; line-height:100%; text-indent:0cm; } .P19 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:center ! important; text-indent:0cm; } .P2 { text-align:right ! important; font-size:14pt; } .P20 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P21 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P22 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; } .P23 { margin-left:0cm; margin-right:0cm; margin-top:0.308cm; margin-bottom:0cm; line-height:100%; text-indent:0cm; } .P24 { margin-left:0cm; margin-right:0cm; margin-top:0.308cm; margin-bottom:0cm; line-height:100%; text-indent:0cm; } .P25 { margin-left:0cm; margin-right:0cm; margin-top:0.141cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P26 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; text-indent:0cm; } .P27 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:0cm; } .P28 { margin-left:0cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P29 { margin-left:0cm; margin-right:0cm; margin-top:0.141cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P3 { text-align:center ! important; } .P30 { margin-left:0.952cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:-0.952cm; } .P31 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P32 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-indent:0cm; } .P33 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; text-indent:0cm; } .P34 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P35 { margin-left:1.27cm; margin-right:0cm; margin-top:0cm; margin-bottom:0cm; line-height:100%; text-align:left ! important; text-indent:0cm; writing-mode:lr-tb; } .P36 { margin-left:0cm; margin-right:0cm; margin-top:0cm; margin-bottom:0cm; line-height:100%; text-align:left ! important; text-indent:0cm; writing-mode:lr-tb; } .P37 { margin-left:2.063cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:-0.793cm; } .P38 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; text-indent:0cm; } .P39 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:0cm; } .P4 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; writing-mode:lr-tb; } .P40 { margin-left:0.952cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:-0.952cm; } .P5 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; writing-mode:lr-tb; } .P6 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; } .P7 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; } .P8 { writing-mode:lr-tb; } .P9 { text-align:center ! important; writing-mode:lr-tb; } .T10 { color:#ffffff; font-size:24pt; text-decoration:underline; font-weight:bold; } .T11 { color:#ffff00; font-size:14pt; font-weight:bold; } .T12 { color:#ffffff; font-size:16pt; font-weight:bold; } .T13 { color:#e5ffff; text-shadow:1pt 1pt; } .T14 { color:#e5ffff; font-size:40pt; text-shadow:1pt 1pt; } .T15 { color:#ffcc00; font-size:24pt; text-shadow:1pt 1pt; } .T16 { color:#ffff00; font-size:24pt; text-shadow:1pt 1pt; } .T17 { font-size:28pt; text-shadow:1pt 1pt; } .T18 { font-size:40pt; text-shadow:1pt 1pt; } .T19 { color:#336699; font-size:40pt; text-shadow:1pt 1pt; font-weight:bold; } .T2 { font-size:12pt; } .T20 { color:#ffff00; font-size:40pt; text-shadow:1pt 1pt; font-weight:bold; } .T21 { color:#990000; font-size:14pt; } .T22 { color:#ffffff; font-weight:bold; } .T23 { font-size:28pt; text-shadow:1pt 1pt; } .T24 { color:#ffc000; font-size:20pt; text-shadow:1pt 1pt; font-weight:bold; } .T25 { font-size:16pt; text-shadow:1pt 1pt; } .T26 { color:#ffff00; font-size:32pt; text-shadow:1pt 1pt; } .T27 { font-size:32pt; text-shadow:1pt 1pt; } .T28 { color:#ffff00; font-size:14pt; } .T29 { color:#ffffff; font-size:14pt; text-decoration:underline; } .T3 { color:#ffffff; font-size:24pt; } .T30 { color:#ff6600; font-size:14pt; font-weight:bold; } .T31 { color:#ffffff; font-size:14pt; } .T32 { color:#ffffff; } .T33 { font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T34 { font-size:18pt; text-shadow:1pt 1pt; } .T35 { color:#ffffff; font-size:16pt; } .T36 { color:#ffc000; font-size:40pt; text-shadow:1pt 1pt; } .T37 { color:#ffffff; font-size:24pt; text-shadow:1pt 1pt; } .T38 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; } .T39 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; font-weight:bold; } .T4 { text-shadow:1pt 1pt; } .T40 { color:#ffffff; font-size:28pt; text-shadow:1pt 1pt; } .T41 { color:#006fb1; } .T42 { color:#ffffff; font-style:italic; } .T43 { color:#ffff00; font-size:32pt; font-weight:bold; } .T44 { color:#ffff00; text-shadow:1pt 1pt; } .T45 { color:#ffff00; font-size:20pt; text-shadow:1pt 1pt; text-decoration:underline; font-weight:bold; } .T46 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; } .T47 { color:#ffcc00; font-size:20pt; text-shadow:1pt 1pt; } .T48 { color:#ffff00; font-size:20pt; text-decoration:underline; font-weight:bold; } .T49 { color:#ffff00; font-size:20pt; font-weight:bold; } .T5 { font-size:24pt; text-shadow:1pt 1pt; } .T50 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; text-decoration:underline; } .T51 { text-shadow:1pt 1pt; } .T52 { text-decoration:underline; } .T53 { color:#336699; font-size:24pt; font-weight:bold; } .T54 { color:#ffffff; font-size:16pt; font-style:normal; text-shadow:none; text-decoration:none ! important; font-weight:normal; } .T55 { color:#ffffff; font-size:16pt; font-style:normal; text-shadow:none; text-decoration:none ! important; font-weight:bold; } .T56 { color:#ffffff; font-size:16pt; font-style:normal; text-shadow:none; text-decoration:underline; font-weight:normal; } .T57 { font-size:20pt; font-weight:bold; } .T58 { font-size:20pt; } .T59 { color:#ffff00; font-size:20pt; } .T6 { font-size:20pt; text-shadow:1pt 1pt; } .T60 { color:#ffff00; font-size:20pt; text-decoration:underline; } .T61 { font-size:20pt; text-decoration:underline; } .T62 { text-shadow:1pt 1pt; text-decoration:underline; } .T63 { color:#ffff00; font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T64 { font-size:24pt; text-shadow:1pt 1pt; text-decoration:underline; } .T7 { text-shadow:1pt 1pt; text-decoration:underline; font-weight:bold; } .T8 { color:#ffffff; font-size:14pt; text-decoration:underline; font-weight:bold; } .T9 { color:#ffffff; font-size:14pt; } <!-- ODF styles with no properties representable as CSS --> .dp1 .dp2 .dp3 .dp4 .T1 { } HIPOTALAMOAREN PATOLOGIAÔÅÆKraneofaringioma. ÔÅÆHaurtzaroan ÔÅÆSupraselarra ÔÅÆHipertentsio endokraneala + hemianopsia bitenporala ÔÅÆKalzifikazioak ÔÅÆTratamendua: kirurgia + RT ÔÅÆGerminoma pineala ÔÅÆBeta-HCG ÔÅÆPubertasun goiztiarra ÔÅÆPinealoma ÔÅÆHipertentsio endokranealaren sindromea AkromegaliaÔÅÆAurpegi, esku eta oinetako hezurren gehiegizko garapena. ÔÅÆHipofisiak hazkuntzaren hormona gehiegi jariatzeagatik gertatzen da Irudi probakRMNErresonantzia magnetiko nuklearra (EMN)TACEskanerra GH ‚Äìren gehiegizkoaFenotipo berezia‚Ä¢Haurtzaroan eta nerabezaroan: gigantismoa ‚Ä¢(garaieraren luzera) ‚Ä¢Helduengan: akromegalia (hezurretako zabalera, oinetako eta eskuetako handitasuna, makroglosia‚Ä¶) Erantsitako patologiaÔÅÆDM. Diabetesa ÔÅÆHTA. Hipertentsioa ÔÅÆEzker bentrikuloko hipertrofia (Ekokardiograma) ÔÅÆHeste lodiaren minbizia: polipoen diagnostiko goiztiarra ÔÅÆLoaldiko apnearen sindromea Sindrome bereziak(familiarrak)ÔÅÆMultiple endocrine neoplasia type 1 ÔÅÆThe McCune‚ÄìAlbright syndrome ÔÅÆFamilial acromegaly ÔÅÆCarney's syndrome (azalaren hiperpigmentazioa , tumore endokrinoak, aurikulako, azalaren eta mukosen mixomak MEN (Neoplasia Endocrina Multiple)1 motako aniztasun neoplasia ÔÅÆTumore Hipofisiko (jariatzailea ala ez) ÔÅÆHiperparatiroidismo primarioa ÔÅÆPankreako tumorea (intsulinoma/glukagonoma‚Ä¶) Pronostikoa DiagnostikoaÔÅÆGH + IGF-I maila basalak handituta daude ÔÅÆPRL-ren neurketa (kasu mistoak) ÔÅÆProba (testak) dinamikoak ÔÅÆAhozko glukosaren gainkarga ÔÅÆTRH testa ÔÅÆKaltzioaren, fosfatoren, D3-ren, PTHren eta gastrinaren neurketak (1 motako MENa aztertzeko) TratamenduaÔÅÆSMS analogoen tratamendua: (aukerakoa) ÔÅÆKirurgia (transesfenoidala/transfrontala) ÔÅÆSendatuz gero: IGF-I normal + GH < 1ng/ml glukosaren ahozko gainkargan (batzuen arabera: < 0.4 ng/ml) ÔÅÆOso helburu zorrotzak jarri dira, akromegaliaren sendatzea bermatzeko Tratamendua (II)ÔÅÆSendatu ezean: ÔÅÆTumorearen arrasto esanguratsuak gelditzen badira edota hazten bada, orduan bigarren ebakuntza aukeratzekoa da ÔÅÆTumoreareren arrasto txikiekin eta kendu ezinik, tratamendu farmakologikoa martxan jartzen da: ÔÅÆSMS-en analogoak ÔÅÆOktreotido LAR (Sandostatin LAR) ÔÅÆLanreotido (Somatulina Autogela) ÔÅÆAgonista dopaminergikoak ÔÅÆBromokriptina ÔÅÆKabergolina (gutxiegitasun mitralaren arriskua) ÔÅÆKinagolide ÔÅÆRT konbentzionala/Radiokirurgia (Gamma knife) SMS analogoak (somatostatina antzekoak) EzaugarriakEfektuak Tumorearen neurriak Jario hormonala Sendatu ezean ÔÅÆSMS analogoen kontrako eerresistenzia kasuetan: Pegvisomant : ÔÅÆGH-ko hartzailearen antagonista bat da ÔÅÆAdi: tumorearen neurri bilakaeraren kontrola KirurgiaÔÅÆEskarmentu handiko hospitaleetan (erreferentzia zentruetan) egin behar da ÔÅÆMikroadenoma kasuetan, sendaketa ÔÅÆOndorioak ÔÅÆDiabetes zaporegabea (behin behinekoa ala behin betikoa): fase hirukoitza: Diabetes zaporegabea-SIADH (ADH sekrezio ezegokiaren sindromea -Diabetes zaporegabea ÔÅÆAurreko-hipofisiaren eskasia: ordezko tratamendua ÔÅÆMeningitisa ÔÅÆFistula PROLAKTINOMA HiperprolaktinemiaÔÅÆFarmakologikoa ÔÅÆDopaminaren inhibitzaileak: clebopride, sulpiride, metoclopramida, haloperidol, risperidona, opi√°ceos, agonistas serotonin√©rgicos (fluoxetina, paroxetina). Klebopride, sulpiride,metoklopramida,haloperidol, risperidona, opiazeoak, agonista serotoninergikoak (fluoxetina, paroxetina)) ÔÅÆHipotalamoaren patologia ÔÅÆHipofisi zurtoinaren patologia: ÔÅÆebakidura, bihurdura, agenesia ÔÅÆHipotiroidismoa ÔÅÆMikro/makroprolaktinoma ÔÅÆAkromegalia ÔÅÆObario polikistosia ÔÅÆBularreko patologia KlinikaEmakumearengan: ÔÅÆGalaktorrea-Amenorrea sindromea ÔÅÆFase luteala motza ÔÅÆIleko irregularrak ÔÅÆLibido gutxi Gizonarengan: ÔÅÆSexu ezintasuna (sexu bulkada gutxi) BietanÔÅÆAntzutasuna ÔÅÆHipotalamo-Hipofisi sintomatologia ÔÅÆHormonen eskasia ÔÅÆKonpresio klinika (makroprolaktinoma) MikroprolaktinomaÔÅÆNeurriak < 10 mm ÔÅÆKlinika ÔÅÆInpotentzia (ernaltzeko ezintasun fisiko, erabatekoa nahiz erlatiboa, baina ez da antzutasuna) (erekzioaren disfuntzio) ÔÅÆAnalitika ÔÅÆPRL-ren eta neurrien proportzioa MakroprolaktinomaÔÅÆNeurriak > 10 mm ÔÅÆHaziera extraselarra (posiblea da) ÔÅÆKlinika ÔÅÆInpotentzia/amenorrea-galaktorrea ÔÅÆBatzutan, hormonen eskasia ÔÅÆTokiko konpresio sintomak DiagnostikoaÔÅÆPRL ÔÅÆInterferentzia farmakologikoa ekiditea ÔÅÆAtsedenaldian aztertu (estresa baztertzeko) ÔÅÆLagin batzuk ÔÅÆPRLren eta tumorearen neurrien proportzioa ÔÅÆGH eta IGF-I ÔÅÆHipotiroidismoa baztertu ÔÅÆMakroprolaktina neurtu Tratamendua (I)ÔÅÆAgonista dopaminergikoak ÔÅÆBromokriptina ÔÅÆTolerantzia (jasamena) ÔÅÆOndorio kaltegarriak ÔÅÆDigestiokoak ÔÅÆHipotentsio ortostatikoa Tratamendua (II)ÔÅÆQuinagolide ÔÅÆEraginkortasun gutxiagoa ÔÅÆAgonista dopaminergikoekin ÔÅÆHormonen normalizazioa ÔÅÆEfektu antitumorala ÔÅÆTumorearen urripena ÔÅÆHaziera ekiditea ÔÅÆGaztaroan mantentzea ÔÅÆMenopausian, batzutan sendaketa. Kentzeko aukera ÔÅÆKirurgia ÔÅÆIndikaziorik ez, erantzunik ezean edota intoleranzia farmakologikoan izan ezik ÔÅÆCirug√≠a ÔÅÆ no indicaci√≥n salvo ÔÅÆNo respondedores o intolerancia farmacol√≥gica ÔÅÆTreatment approaches for patients resistant to dopamine agonists include changing to another dopamine agonist and increasing the dose of the drug as long as there is continued response to the dose increases and no adverse effects with higher doses. ÔÅÆTranssphenoidal surgery is also an option. ÔÅÆClomiphene, gonadotropins, and GnRH can be used if fertility is desired. For those not desiring fertility, estrogen replacement may be used unless there is a macroadenoma, in which case control of tumor growth is also an issue and dopamine agonists are generally necessary. In many patients modest or even no reduction in tumor size may be acceptable as long as there is not tumor growth. Hormone replacement (estrogen or testosterone) may cause a decrease in efficacy of the dopamine agonist ÔÅÆSo that it must be carried out cautiously. HaurdunaldianÔÅÆBromokriptina kabergolina baino hobea da (segurtasun maila kabergolinarena baino handiagoa da) ÔÅÆMikroprolaktinoma kasuetan, agonista dopaminergikoak kendu ÔÅÆMakroprolaktinometan, bromokriptina mantendu ÔÅÆKanpimetria nohizbehinka egin Cushing-en gaixotasunaGiltzurruingaineko patologian ikusiko dugu Jariatzale ez den adenoma ÔÅÆJariatzaleak:maiztasunaren arabera ÔÅÆProlaktinomak ÔÅÆGH ÔÅÆGH eta PRL konbinatutako adenomak ÔÅÆTSH sortzen dutenak (arraroak) MaiztasunaÔÅÆ%10-15 nekropsietan ÔÅÆMaiztasuna: gliomak eta meningiomak ondoren, hirugarrenak ÔÅÆ% 25-30 hipofisiaren tumoreetakoak ÔÅÆ(agian, %10-20¬™, glikoproteina inaktiboak ekoizteagatik: alfa subunitatea, LH, FSH) SintomakÔÅÆLokalak (neurrien arabera): ÔÅÆmakroadenometan, ikusmenaren asaldurak, kanpimetriaren akatsak, buruko mina, hipertenntsio endokraneala‚Ä¶. ÔÅÆMikroprolaktinometan: sintoma propioak (hileko irregulartasuna edota amenorrea sekundarioa (emakumengan), sexu bulkada (gizonengan) + ondoko hormona eskasiaren sintomak Diagn√≥stikoaÔÅÆJario patologikoa eta hormonen eskasia ekidin ÔÅÆAurre hipofisi hormona basalak ÔÅÆAlfa Subunitatea ÔÅÆOsmolaritatea eta elektrolitoak ÔÅÆEMN ÔÅÆBalorazio oftalmolgikoa ÔÅÆKanpimetria ÔÅÆIkusmenaren gaitasuna ÔÅÆBegi-hondokoa TratamenduaÔÅÆKirugia transesfenoidala ÔÅÆRT (berreritzeetan) ÔÅÆSehilabeteko/urteko/biurteko errebisioa ÔÅÆTratamendu farmakologikorik ez ÔÅÆBerreritza: %16a 10 urteetan ÔÅÆBularrako edo birikako minbiziaen metastasiak ÔÅÆPanhipopituitarismoa + DZ ÔÅÆDosi baxuetan emandako RT eraginkorra da ÔÅÆInzidentaloma hipofisarioa ÔÅÆ<10 mm. PRL neurtu + hipofuntzioaren aukera aztertu ÔÅÆEMN hasieran errepikatu ÔÅÆ< 4mm. Hormonak normalak izanez gero, jarraipenik ez ÔÅÆ%4¬™, besterik ez dira hazten ÔÅÆ%12¬™ txikitzen dira
